See today's edition of
DailyUpdates in your
therapeutic area
Search all articles


Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Related Industry Reports:

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Nov 28; In press

Link to PubMed abstract

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ

Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; John P. Fruehauf, University of California, Irvine Medical Center, Irvine; Hoa Nguyen, Daniel Chen, and A

PURPOSEMetastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. PATIENTS AND METHODSPatients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m(2)) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. RESULTS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. CONCLUSIONThe study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.

Keywords: BEAM Bevacizumab Carboplatin Paclitaxel Melanoma